Insiders were net buyers of Vertex, Inc.'s ( NASDAQ:VERX ) stock during the past year. That is, insiders bought ...

This video gives you the fastest and easiest method to understand and sketch parabolas—no complex math required. We break it down step-by-step: finding the vertex, identifying the axis of symmetry, ...

With GPU architectures changing from being entirely graphics-focused and game rendering relying increasingly more on compute ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and ...

Vertex Pharmaceuticals is the worldwide leader in cystic fibrosis treatment -- and its drugs have generated blockbuster revenue. The company has expanded into other therapeutic areas in recent years ...

Investing.com - Morgan Stanley upgraded Vertex Pharmaceuticals (NASDAQ:VRTX) from Equalweight to Overweight on Wednesday, raising its price target to $516.00 from $438.00. The new target represents ...

Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.

--Currently up two consecutive days; up 7.5% over this period --Best two day stretch since the two days ending Dec. 14, 2023, when it rose 13.66% --Up 13.61% year-to-date; on pace for best year since ...

Scientists created a serum containing extracts from a tropical plant and specialized proteins that support hair follicle ...